Abstract The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune imprinting from antecedent SARS-CoV-2 exposure can limit the generation of such antibodies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Baoling Ying
An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals
Keywords H5N1 influenza virus mucosal vaccine chimpanzee-adenovirus vector Syrian hamster clade 2.3.4.4b pre-existing immunity imprinting Introduction H5N1 avian influenza, a highly pathogenic strain of the influenza A virus (HPAI), poses a threat to the poultry and livestock industry and human public health.
Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization
Editor’s summary Booster vaccinations are key to maintaining immunity against evolving viral variants. The question remains whether protection against ancestral and descendant viruses depends on recalled memory B cells or the activation of naïve B cells. Malladi et al. investigated germinal center B cell dynamics in a cohort of participants who had received the bivalent SARS-CoV-2 mRNA booster vaccine targeting the ancestral strain and the Omicron subvariant.
Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein
Abstract SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. GCs are microanatomical sites in lymphoid tissues where diversification and affinity maturation of B cell responses occur. The continuous antigenic evolution of the SARS-CoV-2 spike (S) protein, the major protective B cell target on the virus, has necessitated a regular update of the vaccine antigen composition due to neutralization escape.
Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo Model
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain
Abstract Boosting with mRNA vaccines encoding variant-matched spike proteins has been implemented to mitigate their reduced efficacy against emerging SARS-CoV-2 variants. Nonetheless, in humans, it remains unclear whether boosting in the ipsilateral or contralateral arm with respect to the priming doses impacts immunity and protection.
Intestinal helminth infection impairs vaccine-induced T cell responses and protection against SARS-CoV-2
Abstract Although vaccines have reduced COVID-19 disease burden, their efficacy in helminth infection endemic areas is not well characterized. We evaluated the impact of infection by Heligmosomoides polygyrus bakeri (Hpb), a murine intestinal hookworm, on the efficacy of an mRNA vaccine targeting the Wuhan-1 spike protein of SARS-CoV-2.
Immunoglobulin replacement products confer in vivo protection against SARS-CoV-2 XBB.1.5 Omicron variant despite poor neutralizing activity
ResearchCOVID-19Immunology Open Access | 10.1172/jci.insight.176359 JCI Insight. https://doi.org/10.1172/jci.insight.176359. Copyright © 2024, Zimmerman et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
New Results doi: https://doi.org/10.1101/2022.09.12.507614 ABSTRACT The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains.
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
HIGHLIGHTS • Primary immunization series with mRNA-1273 results in BA.1 breakthrough infection • Primary immunization with BA.1-matched vaccine neutralizes BA.1 but not Wuhan-1 • Both mRNA-1273 and BA.1-matched boosters protect against BA.1 challenge • A BA.1-matched booster induces greater neutralizing antibody responses against BA.1 SUMMARY The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.1. and BA.2) could jeopardize the efficacy of SARS-CoV-2 vaccines.
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice
New Results Baoling Ying, Suzanne M. Scheaffer, Bradley Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin, Kai Wu, Diana Lee, Laura E. Avena, Zhenlu Chong, James Brett Case, LingZhi Ma, Thu Kim, Caralyn Sein, Angela Woods, Daniela Montes Berrueta, Andrea Carfi, Sayda M. Elbashir, Darin K. Edwards, Larissa B. Thackray, View ORCID ProfileMichael S.
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Baoling Ying https://orcid.org/0000-0002-9344-9004, Bradley Whitener https://orcid.org/0000-0001-6652-0701, Laura A. VanBlargan https://orcid.org/0000-0002-8922-8946, Ahmed O. Hassan, Swathi Shrihari, Chieh-Yu Liang https://orcid.org/0000-0003-4624-7212, Courtney E. Karl https://orcid.org/0000-0001-9950-2155, … Show All … , Samantha Mackin https://orcid.org/0000-0003-4518-1274, Rita E. Chen https://orcid.org/0000-0002-5100-7750, Natasha M. Kafai https://orcid.org/0000-0002-3115-3400, Samuel H.
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Pharmacological activation of STING blocks SARS-CoV-2 infection
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, resulting millions of infections and deaths with few effective interventions available. Here, we demonstrate that SARS-CoV-2 evades interferon (IFN) activation in respiratory epithelial cells, resulting in a delayed response in bystander cells.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Baoling
Contact Baoling, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack